Inexpensive copycat pills hurt sales of off-patent drugs that once brought in billions annually, particularly cholesterol fighter Lipitor, the top-selling drug of all time. "Despite continuing revenue challenges due to ongoing product losses of exclusivity and co-promotion expirations, I look forward to the remainder of the year," Chief Executive Officer Ian Read said in the statement. Pfizer confirmed its 2014 profit forecast for earnings per share of $2.20 to $2.30 and revenue of $49.2 billion to $52.3 billion.